Anika Therapeutics, Inc. — Director's Dealing 2021

Mar 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Anika Therapeutics, Inc. (ANIK)
CIK: 0000898437
Period of Report: 2021-03-09

Reporting Person: Loerop James (EVP Business Development)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-09	Restricted Stock Unit	$0.00	A	6705	Acquired		Common Stock (6705)	Direct
2021-03-09	Stock Option (Right to Buy)	$37.40	A	16802	Acquired	2031-03-09	Common Stock (16802)	Direct

Footnotes

F1: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022.

F2: Represents a 10% premium above the closing price of Anika's common stock on the date of grant.

F3: The premium priced stock options vest in three equal annual installments beginning on March 9, 2022.